Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Other EventsItem 8.01.Other Events.
Agile Therapeutics,Inc. (“Agile”) a women’s healthcare company, has had a poster presentation of additional results from the Phase 3 SECURE study of AG200-15 (Twirla®), an investigational, once weekly, low-dose hormonal contraceptive patch accepted at Women’s Health 2018: Translating Research into Clinical Practice being held May4ththrough May6th, 2018 in Arlington, Virginia. On Friday, May4, 2018 James Simon, MD, Clinical Professor at George Washington University will present the poster titled Wearability of a Once-Weekly Low-Dose Contraceptive Pathc in the Phase 3 SECURE Study, which includes data on the adhesion profile and wearability of AG200-15.
The SECURE clinical trial was designed to evaluate the efficacy, safety, and tolerability of AG200-15, also known as Twirla (levonorgestrel/ethinyl estradiol), in a representative population of women seeking birth control. SECURE was a 1-year, multicenter, single-arm, open-label trial in 2032 healthy women aged 18 and over, at 102 experienced investigative sites across the United States.
A copy of Agile’s poster is attached hereto as Exhibit99.1 and is hereby incorporated by reference herein.
Item 8.01.Financial Statements and Exhibits.